The Efficacy of Risedronate in Prevention of Bone Loss in Patients Receiving High Dose Corticosteroid Treatment

Tuen Mun Hospital120 enrolled

Overview

The efficacy of risedronate in prevention of bone loss in patients receiving high dose corticosteroid treatment

We compare the effect of risedronate with placebo in bone mineral density changes in patients receiving high dose corticosteroids for their underlying diseases

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

120

Conditions

Osteoporosis

Interventions

risedronateDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients with various medical conditions who require high dose glucocorticoid treatment: (1) pulse methylprednisolone; (2) oral prednisolone (\>=0.8mg/kg/day) or equivalent for at least 6 weeks. 2. Age\>=18 years and \<75 years. Exclusion Criteria: 1. Pregnant or lactating women. 2. Uncorrected hypocalcemia. 3. History of esophageal stricture. 4. Previous intolerance or hypersenstivity to biphosphonates.

Locations (1)

Tuen Mun Hospital

Hong Kong, China

Outcomes

Primary Outcomes

bone mineral density

Secondary Outcomes

Adverse events, new vertebral fractures

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.